Skyrocketing Stock Alert: Cancer Genetics (NASDAQ: CGIX)

Here comes a cheap biotech company Cancer Genetics (NASDAQ: CGIX)  that soars more than 180% on 1.7 million shares in the premarket due to announcing a merger with Stemonix Sigh Definitive. During the epoch of complicated oncological diseases, the merger could be a smart answer to fight together.

CGIX has been losing significant points recently as its cash is finishing and additional fundraising could be an answer to keep the firm lively. Cancer treatment is so complicated as the best oncology firms always need to improve their approaches and techniques.

After the market opens CGIX may soar even further as its price is still affordable to low budget investors too.

Alex Krakowsky

Editor in Chief. Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life